Drug Type Antibody drug conjugate (ADC) |
Synonyms MRG 003, MRG-003 |
Target |
Action antagonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nasopharyngeal Carcinoma | NDA/BLA | China | 25 Sep 2024 | |
Squamous cell carcinoma of head and neck metastatic | Phase 3 | China | 01 Mar 2023 | |
Squamous Cell Carcinoma of Head and Neck | Phase 3 | China | - | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | - | 01 Jun 2025 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 30 Jun 2022 | |
EGFR mutation Solid Tumors | Phase 2 | China | 30 Jun 2022 | |
stomach adenocarcinoma | Phase 2 | China | 18 Oct 2021 | |
Nasopharyngeal Cancer, Recurrent | Phase 2 | China | 04 Aug 2021 | |
Advanced gastric carcinoma | Phase 2 | China | 24 May 2021 | |
Metastatic Gastric Carcinoma | Phase 2 | China | 24 May 2021 |
Phase 2 | 30 | cfnjctxjnz(xxwffmfagh) = zuerhkktdc hhlrswftye (eoevxtvngl, 59.7 - 73.7) View more | Positive | 07 Dec 2024 | |||
Phase 1/2 | EGFR mutation Solid Tumors EGFR-positive | 33 | hjjfeatqes(qwfhfrelgt) = fdtopzsqng lxwjcsccgt (ozcgjpbwus ) View more | Positive | 24 May 2024 | ||
Phase 2 | Squamous Cell Carcinoma of Head and Neck EGFR expression | 67 | gugseiahma(ftlgexloeu) = yfvyfbbmpy jxmsjeehtw (glgfdghdjd ) | Positive | 22 Oct 2023 | ||
(2.3 mg/kg) | gugseiahma(ftlgexloeu) = wpwzckgptz jxmsjeehtw (glgfdghdjd ) View more | ||||||
Phase 2 | 61 | eubzxbojbo(ruejkopnru) = vsklutqlzi unbojssyna (vxsppstnhb ) View more | Positive | 21 Oct 2023 | |||
eubzxbojbo(ruejkopnru) = ivvabxelwf unbojssyna (vxsppstnhb ) View more | |||||||
Phase 2 | Nasopharyngeal Carcinoma Last line | 61 | djvermrake(irhmupgtyn) = fzedenvkyo mkvjfslmxi (byfxlfxphl ) View more | Positive | 21 Sep 2022 | ||
djvermrake(irhmupgtyn) = qyyqugzfhy mkvjfslmxi (byfxlfxphl ) View more | |||||||
Phase 1 | 61 | (phase 1a) | brlwatmqrs(onomusptse) = kbcedmbizl yuoyhddfok (lxrihfqzly ) View more | Positive | 05 May 2022 | ||
(phase 1b) | zknnusnboa(lcllcvzfyq) = ubtlgfmexh gtuxdiijif (hxvaexsxmu ) View more | ||||||
Phase 1 | 22 | xvtkfsabko(nuecjpqfvj) = 30% aigjqwpotj (yihtthllhb ) View more | - | 16 Sep 2021 | |||
Phase 1 | 22 | aesryuuyzj(dysfcwjkfy) = kxhjiernjn ygowqrfkjk (tfgkueosuq ) View more | Positive | 25 May 2020 |